Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery
Top Cited Papers
- 1 November 2002
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 23 (8) , 327-338
- https://doi.org/10.1002/bdd.325
Abstract
Relative plasma, brain and cerebrospinal fluid (CSF) exposures and unbound fractions in plasma and brain were examined for 18 proprietary compounds in rats. The relationship between in vivo brain‐to‐plasma ratio and in vitro plasma‐to‐brain unbound fraction (fu) was examined. In addition, plasma fu and brain fu were examined for their relationship to in vivo CSF‐to‐plasma and CSF‐to‐brain ratios, respectively. Findings were delineated based on the presence or absence of active efflux. Finally, the same comparisons were examined in FVB vs. MDR 1a/1b knockout mice for a selected P‐glycoprotein (Pgp) substrate. For the nine compounds without indications of active efflux, predictive correlations were observed between ratios of brain‐to‐plasma exposure and plasma‐to‐brain fu (r2 = 0.98), CSF‐to‐brain exposure vs. brain fu (r2 = 0.72), and CSF‐to‐plasma exposure vs. plasma fu (r2 = 0.82). For the nine compounds with indications of active efflux, nonspecific binding data tended to over predict the brain‐to‐plasma and CSF‐to‐plasma exposure ratios. Interestingly, CSF‐to‐brain exposure ratio was consistently under predicted by brain fu for this set. Using a select Pgp substrate, it was demonstrated that the brain‐to‐plasma exposure ratio was identical to that predicted by plasma‐to‐brain fu ratio in MDR 1a/1b knockout mice. In FVB mice, plasma‐to‐brain fu over predicted brain‐to‐plasma exposure ratio to the same degree as the difference in brain‐to‐plasma exposure ratio between MDR 1a/1b and FVB mice. Consistent results were obtained in rats, suggesting a similar kinetic behavior between species. These data illustrate how an understanding of relative tissue binding (plasma, brain) can allow for a quantitative examination of active processes that determine CNS exposure. The general applicability of this approach offers advantages over species‐ and mechanism‐specific approaches. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 26 references indexed in Scilit:
- Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient MiceJournal of Cerebral Blood Flow & Metabolism, 2000
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsPublished by Elsevier ,1994
- Prediction of Drug Distribution in Distribution Dialysis and In Vivo from Binding to Tissues and BloodJournal of Pharmaceutical Sciences, 1993
- Prediction of drug distribution in vivo on the basis of in vitro binding dataBiopharmaceutics & Drug Disposition, 1987
- Physiologic pharmacokinetic models and interanimal species scalingPharmacology & Therapeutics, 1985
- Comparison between in-vivo and in-vitro tissue-to-plasma unbound concentration ratios (Kp,f) of quinidine in ratsJournal of Pharmacy and Pharmacology, 1984
- In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic modelsJournal of Pharmacokinetics and Biopharmaceutics, 1982
- A method to estimate binding constants at variable protein concentrationsJournal of Pharmacy and Pharmacology, 1979
- FACTORS AFFECTING DRUG METABOLISMAnnals of the New York Academy of Sciences, 1971